Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cryo Cell International (CCEL) Shares Outstanding (Weighted Average) (2016 - 2026)

Cryo Cell International's Shares Outstanding (Weighted Average) history spans 17 years, with the latest figure at $8.1 million for Q1 2026.

  • Quarterly results put Shares Outstanding (Weighted Average) at $8.1 million for Q1 2026, changed 0.33% from a year ago — trailing twelve months through Feb 2026 was $8.1 million (changed 0.33% YoY), and the annual figure for FY2025 was $8.1 million, down 0.76%.
  • Shares Outstanding (Weighted Average) for Q1 2026 was $8.1 million at Cryo Cell International, roughly flat from $8.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $8.5 million in Q1 2022 to a low of $8.1 million in Q1 2026.
  • The 5-year median for Shares Outstanding (Weighted Average) is $8.3 million (2024), against an average of $8.3 million.
  • The sharpest move saw Shares Outstanding (Weighted Average) grew 12.63% in 2022, then dropped 2.71% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $8.5 million in 2022, then dropped by 1.47% to $8.3 million in 2023, then decreased by 2.52% to $8.1 million in 2024, then fell by 0.76% to $8.1 million in 2025, then fell by 0.17% to $8.1 million in 2026.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $8.1 million, $8.1 million, and $8.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.